Navigation Links
Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207

Study results to be presented at 2008 ICAAC/IDSA Joint Meeting

ROCKVILLE, Md., Oct. 28 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat infectious diseases of epidemic potential, announces the successful demonstration of synergistic activities and improvement of minimal inhibitory concentration (MIC) resulting from in vitro combination studies of Sequella lead TB drug candidate, SQ109, and Tibotec's lead TB drug candidate, TMC207. Both drug candidates are currently undergoing human clinical studies.

Results from these studies were presented on October 28th at the Interscience Conference on Anti-Microbial Agents and Chemotherapeutics (ICAAC) and Infectious Disease Society of America (IDSA) joint meeting in Washington, DC.

The collaboration between Sequella and Tibotec was designed to investigate in vitro interactions of SQ109 for synergistic, additive, or antagonistic activity in the presence of TMC207, using a number of clinical and laboratory strains of both drug sensitive and drug resistant M. tuberculosis (MTB). In vitro interactions investigated included synergy studies, rate of killing, post antibiotic effect and intracellular activity against MTB in macrophages.

There were no antagonistic activities observed in any combination studies. SQ109 and TMC207 in combination were either synergistic or additive with the various MTB strains and showed increased rate of killing, enhanced post antibiotic effect and intracellular killing activity. Results showed that the SQ109 and TMC207 drug combination was extraordinary potent, with greater than 90% kill of MTB as early as 1 day after drug combination exposure.

Dr. Carol Nacy, CEO of Sequella said, "We are very pleased to be collaborating with Tibotec, a world renowned product development organization, and we look forward to our continuing partnership to examine these important drug synergies in animal models of TB."

The next step of the collaboration will be to complete a series of in vivo studies in animal models of TB, currently underway.

About SQ109

The company's lead drug candidate, SQ109, completing Phase I clinical trials, is a new diamine antibiotic that could replace one or more of the current first-line anti-tuberculosis drugs to simplify or shorten therapy. SQ109 was granted U.S. FDA Fast Track and FDA/EMEA Orphan Drug Designation in 2007.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.

SOURCE Sequella, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
2. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
3. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
4. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
5. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
6. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
7. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
10. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
11. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
(Date:11/30/2015)... 30, 2015 Next week, December 2-3, ... (DoT ) co-located events covering the latest in Medtech ... Things, will draw more than 3,000 design industry professionals ... Center. The events, combined show floor will host more ... --> --> BIOMEDevice features ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, 2015 ... Public Research (the Institute) announced today that it ... a medical device start-up company with technology developed at ... based on publicly-funded research, and bridges early funding gaps ... -based universities and research institutions. ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith has ... Healthcare, a global pioneer in wireless monitoring of ... Boston, MA , Mr. Smith will be ... global commercial strategy.  He will also directly oversee ... build clinical evidence for SensiumVitals, the first early ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Field for Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging ... the anticipated results, once a deal is signed. This quick-read guidance suggests ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant ... , The order will be from the China Disabled Persons’ Federation, a central ... an effective solution for children and adults suffering from severe and profound hearing ...
(Date:11/30/2015)... ... November 30, 2015 , ... Third ... today that it has officially launched a sleek, mobile-ready and user-centric redesigned website. ... company’s new website clearly outlines the benefits that its SEO services provide to ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, ... ... (NAPW) honors Christina Colon as a 2015-2016 inductee into its ... for leadership in pharmacy. NAPW is the nation’s leading networking organization exclusively for ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is excited ... plans on . The multi-carrier insurance exchange platform offers individual vision ... consumers to compare, quote and match plans to meet their needs. , ...
Breaking Medicine News(10 mins):